Mast Therapeutics (MSTX) Reports In-Line Q2 EPS

Mast Therapeutics (NYSE: MSTX) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• B.Riley Starts Neuronetics (STIM) at Buy
• Lightpath Technologies (LPTH) Misses Q4 EPS by 5c